Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder

April 2012

Reps will promote Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder.

They will point out that Saphris (asenapine) is well tolerated.

Saphris seems to cause less weight gain and other metabolic problems than risperidone (Risperdal, etc) or olanzapine (Zyprexa, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Statins whether statins increase the risk of diabetes or cognitive impairment
Neurology & Pain confusion now that patients need to switch from OxyContin to OxyNeo or another opioid
COPD Onbrez (ON-brehz), a new inhaled long-acting beta-agonist for COPD
Insomnia whether insomnia medications increase mortality
Infectious Diseases fewer antibiotic Rxs for acute sinusitis
Antithrombotics how to prevent deep venous thrombosis (DVT) during long trips
Antithrombotics Xarelto will now be used to TREAT deep vein thrombosis (DVT)
Psychiatry Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder
Alzheimer's Disease using coconut oil for Alzheimer's
Pediatrics how to stop bedwetting in children
Lice whether Nyda, Resultz, and Zap are effective for treating head lice
Diabetes ACE inhibitor or ARB to prevent kidney disease